Skeletal Response to Simulated Night Shift
Launched by UNIVERSITY OF COLORADO, DENVER · Sep 29, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how working night shifts, even if only simulated, affects bone health. Researchers want to find out if short-term night shift work can disrupt the natural balance of bone metabolism in healthy adults, and whether returning to a regular day-night sleep pattern can reverse any negative effects. The study will involve monitoring bone turnover markers, which are substances in the body that indicate how bones are being formed and broken down.
To participate in this study, you need to be a healthy adult aged 20 to 40 who usually sleeps 7 to 9 hours at night. Women must be premenopausal and on specific birth control. Participants will need to keep a sleep diary, wear a wrist monitor to track sleep patterns, and spend two separate nights in the hospital for the research. If you're interested, it's important to know there are several health conditions and lifestyle factors that could exclude you, such as being a smoker, having significant sleep disorders, or taking certain medications.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- • Healthy, nonpregnant adults 20-40 years old who habitually sleep 7-9 hours during the biological night
- • o Women must be premenopausal, on continuous combination oral contraception and not breastfeeding.
- • Willing and able to complete a sleep diary, wear a wrist actigraphy monitor and complete a 3-6 week research study including two 4-night inpatient stays.
- • Fully vaccinated against SARS-CoV-2, and willing to produce a negative COVID test result before their first inpatient stay.
- • Exclusion Criteria
- • Regularly go to sleep after midnight.
- • Night shift work within 1 year prior to study.
- • Travel \> 1 time zone within 4 weeks prior to the study or need to travel \>1 time zone during study.
- • Physical activity level/regimen incompatible with inpatient CTRC stay.
- • Current smokers (or within the previous year of study)
- • Positive drug test at screening or inpatient admission
- • BMI \> 30 kg/m2
- • Individuals who are concurrently participating in another research protocol that would influence their safe participation in this study. For example, participants involved in a study that requires blood draws or ingestion of experimental medication as this would increase the risk of participation in our study and/or compromise study results.
- • Any clinically significant unstable medical or surgical condition within the last year (treated or untreated), including history of a clinically significant abnormality of the neurological system (including cognitive disorders or significant head injury) or any history of seizure (including febrile seizure-sleep loss has been used clinically to induce seizures in patients with epilepsy). Given the wide range of illnesses that are encountered in medical practice, it would not be possible to provide a comprehensive list of each and every disease that could serve as grounds for exclusion for the subject. However, the following is a list of illness categories that would certainly be grounds for exclusion: Connective Tissue and Joint Disorders; Neurologic/cognitive Disorders; Musculoskeletal Disorders; Immune Disorders; Chronobiologic Disorders; Cardiovascular Disorders; Respiratory Disorders; Kidney Disorders; Infectious Diseases; Hematopoietic Disorders; Neoplastic Diseases; and Endocrine and Metabolic Diseases.
- * Self-reported or newly diagnosed medical condition that is still being investigated or is not under good control, including those identified on screening labs such as:
- • o Out-of-range values measured on a fasting blood sample: glucose \> 100 mg/dl, thyroid stimulating hormone \<0.5 or \>5.0 uU/ml, abnormal alkaline phosphatase \<39 or \>117 U/l, creatinine, or hemoglobin \<14.5 g/dl men
- • Any clinically significant psychiatric condition, as defined by DSM-V. Individuals with a history of most psychiatric illnesses or psychiatric disorders will be excluded, such as but not limited to depression, anxiety, alcoholism, drug dependency, schizophrenic disorders, and personality disorders (performed by medical history and physician interview). However, a personal history of limited prior counseling, psychotherapy (e.g., for adjustment reactions) will NOT be exclusionary.
- * Evaluation of Psychiatric/Psychological Suitability:
- • Inability to demonstrate a full understanding of the requirements and demands of the study.
- • Each participant will complete psychological screening questionnaires. Exclusionary: Center for Epidemiological Studies Depression (CES-D) \> 16. Subject responses to the CES-D are reviewed immediately and appropriate referrals are made if necessary.
- • Individuals who are unaware of specific psychiatric diagnoses who have a history of having been treated with antidepressants, neuroleptic medications or major tranquilizers will be excluded from study.
- • Use of anti-depressants or any like therapeutics prescribed by a physician is exclusionary
- • Individuals with any clinically significant sleep disorder; Diagnosis or symptoms of sleep disorders (history of significant parasomnia as an adult \[night terrors, frequent sleep walking\], insomnia, including but not limited to hypersomnias such as apnea, periodic limb movements, narcolepsy). Sleep disorders will be screened by self-report and physician interview including use of validated sleep questionnaires (PSQI, Epworth sleepiness scale, and Berlin sleep questionnaire for sleep apnea). The following scores will be used to exclude those with sleep disorders: PSQI \>5, Epworth Sleepiness Scale \>9.
- • Individuals on medications known to affect bone turnover (e.g., glucocorticoids, osteoporosis medications);
- • Use of medications/supplements/drugs that impact sleep or bone metabolism (such as but not limited to sleep medications, marijuana, etc.) within one month (participants can be studied at a later date).
- • Dwelling below Denver altitude (1,600 m) 1 month prior to enrollment.
- • Greater than moderate caffeine (\>500 mg/day) or alcohol use (\>14 standard drinks/ week or \>5 drinks in one sitting)
- • Inability to travel to the CU-AMC campus for study visits.
- • Individuals with restrictive diets (e.g., vegan)
- • Individuals with 25OHD \< 20 ng/mL (may be studied at a later date)
- • Individuals with eGFR \< 60 mL/min/1.73m2 as this is known to affect CTX measurements.
- • Z-score \< -2.0 for bone mineral density at the L-spine, femoral neck, or total hip on baseline DXA as compared to the DXA machine's normative database.
- • Symptoms of active illness (e.g., fever) at time of enrollment; note - participant may be studied at a later date.
- • Restrictive diets that cannot be accommodated by the CTRC Nutrition Core
- • Any other reason that participant may not be able to safely complete the entire study, at PI discretion
About University Of Colorado, Denver
The University of Colorado, Denver, is a leading academic institution dedicated to advancing medical research and improving healthcare outcomes. With a strong emphasis on innovation and collaboration, the university conducts a diverse range of clinical trials aimed at addressing critical health challenges. Its research initiatives are supported by a multidisciplinary team of experts, state-of-the-art facilities, and a commitment to ethical standards and patient safety. By fostering partnerships with local and global communities, the University of Colorado, Denver, strives to translate scientific discoveries into meaningful advancements in clinical practice and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aurora, Colorado, United States
Patients applied
Trial Officials
Christine M Swanson, MD, MCR
Principal Investigator
CU Anschutz
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials